RxDoctor Payments Data

Wichittree Hutton

Nurse Practitioner · York, PANPI 1336550409

Payments from drug & device makers

$3,233in general payments, 2019–2025

Across 165 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$713
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$608
  • Otsuka America Pharmaceutical, Inc.$397
  • Neurocrine Biosciences, Inc.$288
  • Lundbeck LLC$256
  • Alkermes, Inc.$219
  • plus $752 from 7 others

What the payments were for

  • Food & beverage$3,18699%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,233 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,487
Medicare patients
31
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole21$29,556
Atomoxetine Hcl20$2,820
Perphenazine21$2,622
Duloxetine Hcl65$1,731
Bupropion XlBupropion Hcl96$1,635
Quetiapine Fumarate70$1,526
Carbamazepine ErCarbamazepine14$1,365
Buspirone Hcl65$1,221
Trazodone Hcl92$1,126
Sertraline Hcl75$1,068
Venlafaxine Hcl ErVenlafaxine Hcl66$832
Olanzapine19$722
Prazosin Hcl46$711
Hydroxyzine Hcl45$688
Aripiprazole36$640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$397$29,55621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →